Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare, severe neurological diseases. Its lead program, NGN-401, is an investigational one-time gene therapy for Rett syndrome, supported by proprietary EXACT transgene regulation technology intended to better control gene expression in the central nervous system. The pipeline targets high unmet need where conventional gene therapy approaches have been limited for CNS disorders.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -22 | — |
| Q3 2025 | 0 | — | -20.9 | — |
| Q4 2025 | 0 | — | -24.7 | — |
| Q1 2026 | 0 | — | -30.9 | — |
| Q2 2026 | 0 | — | -34.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Monopar Therapeutics Inc. (MNPR), General Catalyst Global Resilience Merger Corp. (GCGR), QVC Group Inc. (QVCG), Gravity Co., Ltd. (GRVY), Kura Sushi USA, Inc. (KRUS), Gemini Space Station, Inc. (GEMI)